Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $15.60.

Several equities research analysts recently commented on KLRS shares. Morgan Stanley started coverage on Kalaris Therapeutics in a research report on Thursday, April 16th. They set an “overweight” rating and a $14.00 target price on the stock. Citizens Jmp cut their target price on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. TD Cowen started coverage on Kalaris Therapeutics in a research report on Monday, June 15th. They set a “buy” rating on the stock. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, June 14th. Finally, Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Wednesday, May 13th.

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju purchased 244,300 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $4.83 per share, with a total value of $1,179,969.00. Following the purchase, the director owned 2,224,147 shares in the company, valued at $10,742,630.01. This represents a 12.34% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 68.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. WHI TRUST Co LLC acquired a new position in Kalaris Therapeutics during the 4th quarter worth approximately $823,000. Barclays PLC acquired a new position in Kalaris Therapeutics during the 4th quarter worth approximately $51,000. Walleye Capital LLC acquired a new position in Kalaris Therapeutics during the 4th quarter worth approximately $95,000. State Street Corp raised its stake in Kalaris Therapeutics by 12.4% during the 4th quarter. State Street Corp now owns 25,410 shares of the company’s stock worth $214,000 after buying an additional 2,800 shares during the period. Finally, Keel Point LLC acquired a new position in Kalaris Therapeutics during the 4th quarter worth approximately $86,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Price Performance

Shares of Kalaris Therapeutics stock opened at $4.40 on Tuesday. Kalaris Therapeutics has a one year low of $2.14 and a one year high of $11.88. The stock’s 50-day moving average is $5.16 and its 200 day moving average is $7.36. The firm has a market cap of $104.68 million, a price-to-earnings ratio of -2.05 and a beta of 0.15.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06. On average, sell-side analysts expect that Kalaris Therapeutics will post -2.05 EPS for the current fiscal year.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.